Global Radiopharmaceuticals Industry PowerPoint PPT Presentations

Global Radiopharmaceuticals Industry Analysis http://www.reportsnreports.com/reports/274695-global-radiopharmaceuticals-market-insight.html . The new innovations in nuclear medicine to target coronary heart disease, Alzheimer’s disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%.

Global Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends andForecast To 2024

Prevalence of diseases such as cancer and cardiovascular diseases are increasing rapidly across the globe due to aging population, unhealthy food habits, and rising obesity. For instance, according to the American Heart Association, cardiovascular diseases alone accounts for 17.3 million deaths each year, which is more than the deaths caused due to cancer.

The global radiopharmaceuticals market was worth USD 4.31 Billion in 2020 and is further projected to reach USD 6.43 Billion by 2027, at a CAGR of 6.0% during 2021-2027 (forecast period).

In-depth research of the Radiopharmaceuticals Market helps to provide the relevant emerging trends and growth opportunities – report given by TBRC. https://bit.ly/3mmqkmo

The radiopharmaceuticals market is then expected to grow at a CAGR of 5.6% from 2025 and reach $7,507.3 million in 2030.

Latest research Radiopharmaceuticals Market, released by The Business Research Company with 130+ pages of analysis on business strategy and emerging industry players. https://bit.ly/3mmqkmo

The Global And China Radiopharmaceuticals Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Radiopharmaceuticals industry.

The major players covered in the global radiopharmaceuticals market are Siemens Healthcare Private Limited, Bayer, GE Healthcare.... @ @ https://bit.ly/3xiqYIu

Global Radiopharmaceuticals Market by The Business Research Company is segmented as Oncology, Cardiology, Gastroenterology, Neuroendocrinnology, Neurology https://bit.ly/3iywX58

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021).

The world radiopharmaceuticals market is expected to generate revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.

Global Diagnostic Radiopharmaceuticals & Contrast Media Market 2023 is an extensive, professional analysis bringing market research data which is pertinent to new market entrants and recognized players. The report covers data that makes the record a resource for analysts, managers, Diagnostic Radiopharmaceuticals & Contrast Media industry experts as well as important people to get self-analyze along with ready-to-access study together side graphs and tables. Mixing the information integration and research capacities with the findings, this Diagnostic Radiopharmaceuticals & Contrast Media report has forecast the strong rise of this market in product sections and every geography.

Diagnostic Radiopharmaceuticals & Contrast Media market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diagnostic Radiopharmaceuticals & Contrast Media market will be able to gain the upper hand as they use the report as a powerful resource.

2018 Market Research Report on Radiopharmaceuticals was a professional and depth research report on Radiopharmaceuticals that you would know the world's major regional market conditions of Radiopharmaceuticals, the main region including North American, Europe and Asia etc., and the main country including United States ,Germany ,Japan and China etc..

Radiopharmaceuticals in Nuclear Medical market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Radiopharmaceuticals in Nuclear Medical market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.

Global Radiopharmaceuticals Market, According to Data Bridge Market Research new Market report “By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast To 2024″ is projected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Global Radiopharmaceuticals Market According to Data Bridge Market Research new Market report– Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.

The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.

The global radiopharmaceuticals market size was valued at $5.2 billion in 2022, and is projected to reach $13.7 billion by 2032, growing at a CAGR of 10.2% from 2023 to 2032.

The global Radiopharmaceuticals/Nuclear Medicine Market was valued at US$ 5605 Million in 2022 and is anticipated to grow at US$ 9327 Million by 2029 recording a CAGR of 9.3% during the forecast period 2023-2029. Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=17441

Radiopharmaceuticals Market Analysis

According to the latest research report by IMARC Group, The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032. More Info:- https://www.imarcgroup.com/alpha-emitter-market

Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Bracco Imaging Bayer Mallinckrodt Nordion Triad Isotopes Lantheus IBA Group

Global Radiopharmaceutical Theragnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product Type, Radioisotope, Source, Application, Indication, and End User,” the market is expected to grow from US$ 1,814.58 million in 2022 to US$ 3,441.97 million by 2028; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028

Big Market Research “Global Contrast MediaContrast Agents Market” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/global-contrast-mediacontrast-agents-2015-2019-market Contrast mediacontrast agents are chemicals used in diagnostic imaging procedures such as CT scans, MRIs, X-rays, ultrasounds, and related procedures. They enhance the internal structure of the body and provide high-quality images, which help in providing an accurate diagnosis. It is widely used in radiology, interventional radiology, and interventional cardiology.

A new report available with decisiondatabases.com on RadiopharmaceuticalsMarket which provides an in-depth analysis during the forecast period. This report focuses on top manufactures with capacity, production, price, revenue and Market share.

Automated Radiosynthesis modules drive the production of radiotracer for PET and SPECT (Single-Photon Emission Computed Tomography) imaging in decentralized settings. These modules are user friendly, simple to set up, and offer scope of customized formulations of radiotracer for diagnostic and therapy administration, and hence their adoption will be increasing in near future. Automated Radiosynthesis Modules Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $32 million by 2022, registering a CAGR of 6.6% during the period 2016 - 2022.North America accounted for the largest share in terms of both market revenues and unit volumes, whereas Asia-Pacific region is expected to witness fastest growth rate during the forecast period. Read Full Report here: https://www.alliedmarketresearch.com/automated-radio-synthesis-modules-market Download Sample report @ https://www.alliedmarketresearch.com/request-free-sample/1761

Strategic foundation roles: Industry structure Strategic foundation Industry structure Customer value Business capabilities Competitive position To capture basic ...

Nuclear Medicine/ Radiopharmaceuticals Market is expected to garner $8,207.5 million by 2022. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.

Looking forward, the nuclear medicine equipment market value is projected to reach a strong growth during the forecast period (2022-2027). More info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market

This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017. The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%. Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimer’s disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.

Department of Nuclear Engineering, University of California, Berkeley ... Sterilization (screw worm, Mediterranean fruit flies, gypsy moths) ...

According to #TechSci Research report, Global Nuclear Imaging Equipment Market stood at USD4054.46 million in 2020 and is expected to grow at a CAGR of 6.51% by 2026. Gain More Insight: https://bit.ly/3v29zB4 Get Sample Report: https://bit.ly/3KdYyVJ Press Release: https://bit.ly/3LGMv3y Website: https://www.techsciresearch.com/ Market Research News: https://techsciblog.com/

Marketreportsonchina.com presents a report on “Global Central Nervous System Biomarkers : Segmentation and Forecast 2015 - 2021”. http://www.marketreportsonchina.com/life-sciences-market-research-reports-18404/global-central-nervous-system-biomarkers-by-united-states-canada-india-china-japan-united-kingdom.html The global market value of the Global CNS Biomarker market is expected to be a billion dollar opportunity by 2015.

Get more details @ http://bit.ly/2oX0vzB Genitourinary Drugs Market Size, Industry Analysis Report, Regional Outlook (U.S., Germany, UK, Italy, Russia, China, India, Japan, South Korea, Brazil, Mexico, Saudi Arabia, UAE, South Africa), Application Growth Potential, Competitive Market Growth & Forecast, 2016 – 2024

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and a pplications.Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Germany, France, Italy, Spain, U.K., Russia, and Rest of Europe) to provide in-depth information on the European scenario.

Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

The Radiopharmaceutical/Nuclear Medicine Market Report offers a complete picture of industry trends and factors along with quantitative data based on historical data and from various sources. Apart from this, the report also provides the market outlook, growth, share, size, opportunity and forecast during 2019-2025. Further, the report focuses on competitive landscape including company profiles of leading key players along with industry demand, future capacities, key mergers & acquisitions, financial overview in the global market of radiopharmaceutical/nuclear medicine.

[No of pages - 346 ] Browse 142 market tables and 44 figures/charts on Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13),[SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

The global radiopharmaceuticals market size is projected to reach USD 9.54 billion by 2026. According to a report published by Fortune Business Insights, titled “Radiopharmaceuticals Market Size, Share & Industry Analysis, By Type (PET Radiopharmaceuticals, SPECT Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End User (Hospitals & Clinics, Diagnostic Centres, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 4.86 billion in 2018. Driven by increasing number of successful clinical trials, the market will exhibit a CAGR of 9.0% from 2019-2026. For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812

The report covers the major unsaturated polyester resin (UPR) markets including Orthophthalic, Isophthalic, and DCPD resins. It further divides the market on the basis of types, industry verticals, and geography. The report analyses the market for unsaturated polyester resins with respect to drivers, opportunities, and winning imperatives related to the industry.

The nuclear medicine market is projected to reach USD 5.26 billion by 2023 from USD 3.95 billion in 2018. Factors such as the growing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99, are driving market growth.

The Business Research Company offers nuclear medicine diagnostics market research report 2023 with industry size, share, segments and market growth

Lecture at European School on Nuclear Chemistry and Industry

The global nuclear medicine equipment market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.8% during 2024-2032. More Info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market

Radiopharmaceuticals is a medical specialty that uses specific radiotracers, and have emerged as an efficient imaging technology in the field of nuclear medicine. The non-invasive nature of radiopharmaceuticals has quickened the diagnosis of various diseases such as cardiovascular diseases, neurological disorders, and cancers.

The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.

The global metastatic Castration-Resistant Prostate Cancer market is expected to register a robust revenue CAGR over the forecast period owing to increased cases of prostate cancer. For instance, prostate cancer is the second most frequent cancer in males and fourth most prevalent cancer in general population.

The nuclear medicine is an intricate branch of medical science that uses radiopharmaceuticals for detection and diagnostic procedures. The radiopharmaceuticals consist of radioisotopes produced through particle accelerator such as the medical cyclotron and are used for targeted therapy, detection based imaging and therapeutics. With advancement in medical technology, the imaging and diagnostic devices have evolved significantly.

According to the latest research report by IMARC Group, The global nuclear medicine equipment market size reached US$ 2.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 6.65% during 2023-2028. More Info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market

The report on United States Parkinson's Disease Drug Industry 2015 Market Research Report added by DecisionDatabases.com gives an in depth industry analysis of the market. It covers the costing, sales, revenue details and forecasts.

Global Radiopharmaceutical Theragnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product Type, Radioisotope, Source, Application, Indication, and End User,” the market is expected to grow from US$ 1,814.58 million in 2022 to US$ 3,441.97 million by 2028; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028

According to the latest research report by IMARC Group, The global positron emission tomography market size reached US$ 1,084 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,512 Million by 2028, exhibiting a growth rate (CAGR) of 5.9% during 2023-2028. More Info:- https://www.imarcgroup.com/positron-emission-tomography-market